Search

Your search keyword '"Pirmohamed, Munir"' showing total 2,421 results
Start Over Author "Pirmohamed, Munir"
2,421 results on '"Pirmohamed, Munir"'

4. All‐cause and liver‐related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank

Author

Whitfield, John B, Seth, Devanshi, Morgan, Timothy R, Aithal, Guruprasad P, Atkinson, Stephen R, Bataller, Ramon, Botwin, Gregory, Chalasani, Naga P, Cordell, Heather J, Daly, Ann K, Darlay, Rebecca, Day, Christopher P, Eyer, Florian, Foroud, Tatiana, Gleeson, Dermot, Goldman, David, Haber, Paul S, Jacquet, Jean‐Marc, Liang, Tiebing, Liangpunsakul, Suthat, Masson, Steven, Mathurin, Philippe, Moirand, Romain, Moreno, Christophe, Morgan, Marsha Y, Mueller, Sebastian, Müllhaupt, Beat, Nagy, Laura E, Nahon, Pierre, Nalpas, Bertrand, Naveau, Sylvie, Perney, Pascal, Pirmohamed, Munir, Schwantes‐An, Tae‐Hwi, Seitz, Helmut K, Soyka, Michael, Stickel, Felix, Thompson, Andrew, Thursz, Mark R, and Trepo, Eric

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Substance Misuse, Liver Disease, Nutrition, Brain Disorders, Alcoholism, Alcohol Use and Health, Clinical Research, Cancer, Oral and gastrointestinal, Good Health and Well Being, Humans, Male, Female, Alcoholism, Alcohol Drinking, Biological Specimen Banks, Risk Factors, Cardiovascular Diseases, Liver, United Kingdom, alcohol, alcohol dependence, all-cause mortality, excessive drinking, liver disease, GenomALC Consortium, Neurosciences, Psychology, Substance Abuse, Clinical sciences, Biological psychology, Clinical and health psychology
Abstract

BackgroundHigh alcohol intake is associated with increased mortality. We aimed to identify factors affecting mortality in people drinking extreme amounts of alcohol.MethodsWe obtained information from the UK Biobank on approximately 500,000 participants aged 40-70 years at baseline assessment in 2006-2010. Habitual alcohol intake, lifestyle and physiological data, laboratory test results, and hospital diagnoses and death certificate data (to June 2020) for 5136 men (2.20% of male participants) and 1504 women (0.60%) who reported consuming ≥80 or ≥50 g/day, respectively, were used in survival analysis.ResultsMortality hazard ratios for these excessive drinkers, compared to all other participants, were 2.02 (95% CI 1.89-2.17) for all causes, 1.89 (1.69-2.12) for any cancer, 1.87 (1.61-2.17) for any circulatory disease, and 9.40 (7.00-12.64) for any liver disease. Liver disease diagnosis or abnormal liver function tests predicted not only deaths attributed to liver disease but also those from cancers or circulatory diseases. Mortality among excessive drinkers was also associated with quantitative alcohol intake; diagnosed alcohol dependence, harmful use, or withdrawal syndrome; and current smoking at assessment.ConclusionsPeople with chronic excessive alcohol intake experience decreased average survival, but there is substantial variation in their mortality, with liver abnormality and alcohol dependence or other alcohol use disorders associated with a worse prognosis. Clinically, patients with these risk factors and high alcohol intake should be considered for early or intensive management. Research can usefully focus on the factors predisposing to dependence or liver abnormality.

Published
2022

5. Roadmap to 2030 for Drug Evaluation in Older Adults

Author

Liu, Qi, Schwartz, Janice B, Slattum, Patricia W, Lau, SW Johnny, Guinn, Daphne, Madabushi, Rajanikanth, Burckart, Gilbert, Califf, Robert, Cerreta, Francesca, Cho, Carolyn, Cook, Jack, Gamerman, Jamie, Goldsmith, Paul, Graaf, Piet H, Gurwitz, Jerry H, Haertter, Sebastian, Hilmer, Sarah, Huang, Shiew‐Mei, Inouye, Sharon K, Kanapuru, Bindu, Pirmohamed, Munir, Posner, Phil, Radziszewska, Barbara, Talbot, H Keipp, and Temple, Robert

Subjects
Clinical Trials and Supportive Activities, Clinical Research, Aging, Patient Safety, Brain Disorders, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Drug Evaluation, Drug-Related Side Effects and Adverse Reactions, Humans, Polypharmacy, Prevalence, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy
Abstract

Changes that accompany older age can alter the pharmacokinetics (PK), pharmacodynamics (PD), and likelihood of adverse effects (AEs) of a drug. However, older adults, especially the oldest or those with multiple chronic health conditions, polypharmacy, or frailty, are often under-represented in clinical trials of new drugs. Deficits in the current conduct of clinical evaluation of drugs for older adults and potential steps to fill those knowledge gaps are presented in this communication. The most important step is to increase clinical trial enrollment of older adults who are representative of the target treatment population. Unnecessary eligibility criteria should be eliminated. Physical and financial barriers to participation should be removed. Incentives could be created for inclusion of older adults. Enrollment goals should be established based on intended treatment indications, prevalence of the condition, and feasibility. Relevant clinical pharmacology data need to be obtained early enough to guide dosing and reduce risk for participation of older adults. Relevant PK and PD data as well as patient-centered outcomes should be measured during trials. Trial data should be analyzed for differences in PK, PD, effectiveness, and safety arising from differences in age or from the presence of conditions common in older adults. Postmarket evaluations with real-world evidence and drug labeling updates throughout the product lifecycle reflecting new knowledge are also needed. A comprehensive plan is needed to ensure adequate evaluation of the safety and effectiveness of drugs in older adults.

Published
2022

7. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers

Author

Whitfield, John B, Schwantes-An, Tae-Hwi, Darlay, Rebecca, Aithal, Guruprasad P, Atkinson, Stephen R, Bataller, Ramon, Botwin, Greg, Chalasani, Naga P, Cordell, Heather J, Daly, Ann K, Day, Christopher P, Eyer, Florian, Foroud, Tatiana, Gleeson, Dermot, Goldman, David, Haber, Paul S, Jacquet, Jean-Marc, Liang, Tiebing, Liangpunsakul, Suthat, Masson, Steven, Mathurin, Philippe, Moirand, Romain, McQuillin, Andrew, Moreno, Christophe, Morgan, Marsha Y, Mueller, Sebastian, Müllhaupt, Beat, Nagy, Laura E, Nahon, Pierre, Nalpas, Bertrand, Naveau, Sylvie, Perney, Pascal, Pirmohamed, Munir, Seitz, Helmut K, Soyka, Michael, Stickel, Felix, Thompson, Andrew, Thursz, Mark R, Trépo, Eric, Morgan, Timothy R, Seth, Devanshi, and Consortium, GenomALC

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Liver Cancer, Genetics, Liver Disease, Clinical Research, Substance Misuse, Genetic Testing, Cancer, Alcoholism, Alcohol Use and Health, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Metabolic and endocrine, Oral and gastrointestinal, Good Health and Well Being, Adult, Alcohol Drinking, Case-Control Studies, Cohort Studies, Diabetes Mellitus, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Liver Cirrhosis, Alcoholic, Male, Middle Aged, Polymorphism, Single Nucleotide, Risk Assessment, Hepatocellular carcinoma, risk stratification, chronic alcohol use, genome-wide association, single nucleotide polymorphism, coffee, GenomALC Consortium, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsOnly a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk.MethodsThree cohorts (GenomALC-1: n = 1,690, GenomALC-2: n = 3,037, UK Biobank: relevant n = 6,898) with a history of heavy alcohol consumption (≥80 g/day (men), ≥50 g/day (women), for ≥10 years) were included. Cases were participants with alcohol-related cirrhosis. Controls had a history of similar alcohol consumption but no evidence of liver disease. Risk scores were computed from up to 8 genetic loci identified previously as associated with alcohol-related cirrhosis and 3 clinical risk factors. Score performance for the stratification of alcohol-related cirrhosis risk was assessed and compared across the alcohol-related liver disease spectrum, including hepatocellular carcinoma (HCC).ResultsA combination of 3 single nucleotide polymorphisms (SNPs) (PNPLA3:rs738409, SUGP1-TM6SF2:rs10401969, HSD17B13:rs6834314) and diabetes status best discriminated cirrhosis risk. The odds ratios (ORs) and (95% CIs) between the lowest (Q1) and highest (Q5) score quintiles of the 3-SNP score, based on independent allelic effect size estimates, were 5.99 (4.18-8.60) (GenomALC-1), 2.81 (2.03-3.89) (GenomALC-2), and 3.10 (2.32-4.14) (UK Biobank). Patients with diabetes and high risk scores had ORs of 14.7 (7.69-28.1) (GenomALC-1) and 17.1 (11.3-25.7) (UK Biobank) compared to those without diabetes and with low risk scores. Patients with cirrhosis and HCC had significantly higher mean risk scores than patients with cirrhosis alone (0.76 ± 0.06 vs. 0.61 ± 0.02, p = 0.007). Score performance was not significantly enhanced by information on additional genetic risk variants, body mass index or coffee consumption.ConclusionsA risk score based on 3 genetic risk variants and diabetes status enables the stratification of heavy drinkers based on their risk of cirrhosis, allowing for the provision of earlier preventative interventions.Lay summaryExcessive chronic drinking leads to cirrhosis in some people, but so far there is no way to identify those at high risk of developing this debilitating disease. We developed a genetic risk score that can identify patients at high risk. The risk of cirrhosis is increased >10-fold with just two risk factors - diabetes and a high genetic risk score. Risk assessment using this test could enable the early and personalised management of this disease in high-risk patients.

Published
2022

8. The Implementation of Pharmacogenetics in the United Kingdom

Author

McDermott, John H., Sharma, Videha, Keen, Jessica, Newman, William G., Pirmohamed, Munir, Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Wang, KeWei, Editorial Board Member, Cascorbi, Ingolf, editor, and Schwab, Matthias, editor

Published
2023
Full Text
View/download PDF

11. Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry

Author

Asiimwe, Innocent G., Blockman, Marc, Cavallari, Larisa H., Cohen, Karen, Cupido, Clint, Dandara, Collet, Davis, Brittney H., Jacobson, Barry, Johnson, Julie A., Lamorde, Mohammed, Limdi, Nita A., Morgan, Jennie, Mouton, Johannes P., Muyambo, Sarudzai, Nakagaayi, Doreen, Ndadza, Arinao, Okello, Emmy, Perera, Minoli A., Schapkaitz, Elise, Sekaggya-Wiltshire, Christine, Semakula, Jerome R., Tatz, Gayle, Waitt, Catriona, Yang, Guang, Zhang, Eunice J., Jorgensen, Andrea L., and Pirmohamed, Munir

Published
2024
Full Text
View/download PDF

13. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management

Author

Dale, Caroline E., Takhar, Rohan, Carragher, Raymond, Katsoulis, Michail, Torabi, Fatemeh, Duffield, Stephen, Kent, Seamus, Mueller, Tanja, Kurdi, Amanj, Le Anh, Thu Nguyen, McTaggart, Stuart, Abbasizanjani, Hoda, Hollings, Sam, Scourfield, Andrew, Lyons, Ronan A., Griffiths, Rowena, Lyons, Jane, Davies, Gareth, Harris, Daniel, Handy, Alex, Mizani, Mehrdad A., Tomlinson, Christopher, Thygesen, Johan H., Ashworth, Mark, Denaxas, Spiros, Banerjee, Amitava, Sterne, Jonathan A. C., Brown, Paul, Bullard, Ian, Priedon, Rouven, Mamas, Mamas A., Slee, Ann, Lorgelly, Paula, Pirmohamed, Munir, Khunti, Kamlesh, Morris, Andrew D., Sudlow, Cathie, Akbari, Ashley, Bennie, Marion, Sattar, Naveed, and Sofat, Reecha

Published
2023
Full Text
View/download PDF

18. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Author

Buunk, Annemarie, Goossens, Hanneke, Baas, Gert, Algera, Maartje, Schuil-Vlassak, Evelyn, Ambagts, Thijs, De Hoog-Schouten, Leonie, Musaafir, Sara, Bosch, Roelof, Tjong, Carol, Steeman, Sanne, Van der Plas, Martine, Baldew, Glenn, Den Hollander, Iris, De Waal, Zacharias, Heijn, Aurele, Nelemans, Leen, Kouwen-Lubbers, Kirsten, Van Leeuwen, Maartje, Hoogenboom, Sacha, Van Doremalen, Jacobine, Ton, Célin, Beetstra, Bastien, Meijs, Veronique, Dikken, Jan, Dubero, Dasha, Slager, Mark, Houben, Tom, Kanis, Thomas, Overmars, Wietske, Nijenhuis, Marga, Steffens, Michael, Bergs, Ingmar, Karamperis, Kariofyllis, Siamoglou, Stavroula, Ivantsik, Ouliana, Samiou, Georgia-Chryssa, Kordou, Zoe, Tsermpini, Evira, Ferentinos, Panagiotis, Karaivazoglou, Aikaterini, Rigas, George, Gerasimou, Harilaos, Voukelatou, Georgia, Georgila, Eleni, Tsermpini, Evangelia Eirini, Mendrinou, Efrossyni, Chalikiopoulou, Konstantina, Kolliopoulou, Alexandra, Mitropoulos, Konstantinos, Stratopoulos, Apostolos, Liopetas, Ioannis, Tsikrika, Athina, Barba, Evangelia, Emmanouil, Georgia, Stamopoulou, Theano, Stathoulias, Andreas, Giannopoulos, Panagiotis, Kanellakis, Filippos, Bartsakoulia, Marina, Katsila, Theodora, Douzenis, Athanassios, Gourzis, Filippos, Assimakopoulos, Konstantinos, Bignucolo, Alessia, Dal Cin, Lisa, Comello, Francesco, Mezzalira, Silvia, Puglisi, Fabio, Spina, Michele, Foltran, Luisa, Guardascione, Michela, Buonadonna, Angela, Bartoletti, Michele, Corsetti, Serena, Ongaro, Elena, Da Ros, Lucia, Bolzonello, Silvia, Spazzapan, Simon, Freschi, Andrea, Di Nardo, Paola, Palazzari, Elisa, Navarria, Federico, Innocente, Roberto, Berretta, Massimiliano, D'Andrea, Mario, Angelini, Francesco, Diraimo, Tania, Favaretto, Adolfo, Dávila-Fajardo, Cristina Lucía, Díaz-Villamarín, Xando, Martínez-González, Luis Javier, Antúnez-Rodríguez, Alba, Moreno-Escobar, Eduardo, Fernández-Gómez, Ana Estefanía, García-Navas, Paloma, Bautista-Pavés, Alicia Bautista Pavés, Burillo-Gómez, Francisco, Villegas-Rodríguez, Inmaculada, Sánchez-Ramos, Jesús Gabriel, Antolinos-Pérez, Mª José, Rivera, Ricardo, Martínez-Huertas, Susana, Thomas-Carazo, Jesús, Yañez-Sanchez, Jose Julio, Blancas-López-Barajas, Mª Isabel, García-Orta, Rocío, González-Astorga, Beatriz, Rodríguez-González, Carlos José, Ruiz-Carazo, Francisco Javier, Pérez-Campos, Manuel, Cano-Herrera, Irene, Herrera, Rosa, Gil-Jiménez, Teresa, Delgado-Ureña, Mª Teresa, Triviño-Juarez, Jose Matías, Campos-Velázquez, Salustiano, Alcántara- Espadafor, Silvia, Moreno Aguilar, Maria Rosario, Ontiveros- Ortega, Maria Carmen, Carnerero-Córdoba, Lidia, Guerrero-Jiménez, Margarita, Legeren- Álvarez, Marta, Yélamos-Vargas, Marisol, Castillo-Pérez, Isabel, Aomar-Millán, Ismael, Anguita-Romero, Manuel, Sánchez-García, María José, Sequero-Lopez, Silvia, Faro-Miguez, Naya, López-Fernández, Silvia, Leyva-Ferrer, Rosario Nieves, Herrera-Gómez, Norberto, Pertejo-Manzano, Laura, Pérez-Gutierrez, Eva Mª, Martín-de la Higuera, Antonio J., Plaza-Carrera, Jose, Baena-Garzón, Flor, Toledo-Frías, Pablo, Cruz-Valero, Inés, Chacón-McWeeny, Verónica, Gallardo- Sánchez, Isabel, Arrebola, Antonio, Guillén-Zafra, Lucía, Ceballos-Torres, Ángel, Guardia-Mancilla, Plácido, Guirao-Arrabal, Emilio, Canterero-Hinojosa, Jesús, Velasco-Fuentes, Sara, Sánchez- Cano, Daniel, Aguilar-Jaldo, Mª del Pilar, Caballero-Borrego, Juan, Praznik, Monika, Slapšak, Urška, Voncina, Blaz, Rajter, Branka, Škrinjar, Andrej, Marjetic Ulcakar, Angelika, Zidanšek, Anja, Stegne Ignjatvic, Tea, Mazej Poredoš, Barbara, Vivod Pecnik, Živka, Poplas Susic, Tonka, Juteršek, Milojka, Klen, Jasna, Skoporc, Janja, Kotar, Tjaša, Petek Šter, Marija, Zvezdana Dernovšk, Mojca, Mlinšek, Gregor, Miklavcic, Petra, Plemenitaš Ilješ, Anja, Grašic Kuhar, Cvetka, Oblak, Irena, Stražišar, Branka, Štrbac, Danijela, Matos, Erika, Mencinger, Marina, Vrbnjak, Marko, Saje, Marko, Radovanovic, Mirjana, Jeras, Katja, Bukovec, Lucija, Terzic, Tea, Minichmayr, Iris, Nanah, Abdulaziz, Nielsen, Elisabet, Zou, Yuanxi, Lauschke, Volker, Johansson, Inger, Zhou, Yitian, Nordling, Åsa, Aigner, Christof, Dames-Ludwig, Marlies, Monteforte, Rossella, Sunder-Plassmann, Raute, Steinhauser, Corinna, Sengoelge, Guerkan, Winnicki, Wolfgang, Schmidt, Alice, Vasileios, Fragoulakis, Fontana, Vanessa, Hanson, Anita, Little, Margaret, Hornby, Rachael, Dello Russo, Cinzia, French, Stephanie, Hampson, Jamie, Gumustekin, Mukaddes, Anyfantis, George, Hampson, Lucy, Lewis, David, Westhead, Ruth, Prince, Clare, Rajasingam, Arjunan, Swen, Jesse J, van der Wouden, Cathelijne H, Manson, Lisanne EN, Abdullah-Koolmees, Heshu, Blagec, Kathrin, Blagus, Tanja, Böhringer, Stefan, Cambon-Thomsen, Anne, Cecchin, Erika, Cheung, Ka-Chun, Deneer, Vera HM, Dupui, Mathilde, Ingelman-Sundberg, Magnus, Jonsson, Siv, Joefield-Roka, Candace, Just, Katja S, Karlsson, Mats O, Konta, Lidija, Koopmann, Rudolf, Kriek, Marjolein, Lehr, Thorsten, Mitropoulou, Christina, Rial-Sebbag, Emmanuelle, Rollinson, Victoria, Roncato, Rossana, Samwald, Matthias, Schaeffeler, Elke, Skokou, Maria, Schwab, Matthias, Steinberger, Daniela, Stingl, Julia C, Tremmel, Roman, Turner, Richard M, van Rhenen, Mandy H, Dávila Fajardo, Cristina L, Dolžan, Vita, Patrinos, George P, Pirmohamed, Munir, Sunder-Plassmann, Gere, Toffoli, Giuseppe, and Guchelaar, Henk-Jan

Published
2023
Full Text
View/download PDF

19. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study

Author

Alexander, Daniel C, Asiimwe, Innocent G, Ball, Simon, Bennett, Frances, Borges, Maria Carolina, Butterworth, Adam, Chaturvedi, Nishi, Chopade, Sandesh, Clarkson, Christopher, Cox, Martin, Dale, Caroline, Denaxas, Spiros, Dunca, Diana, Engmann, Jorgen E, Fernandez-Sanles, Alba, Finan, Chris, Fitzpatrick, Natalie, Gallagher, Jean, Gonzalez-Izquierdo, Arturo, Gratton, Jasmine, Gross, Christian, Hemingway, Harry, Henry, Albert, Hidajat, Mira, Hingorani, Aroon, Hukerikar, Nikita, Jorgensen, Andrea, Joshi, Roshni, Katsoulis, Michail, Kuan, Valerie, Kumar, Rashmi, Lai, Alvina G, Langenberg, Claudia, Lawlor, Deborah, Mancini, Mary, Miller, Diane, Ogden, Margaret, Ozyigit, Eda B, Patel, Shilpa, Pirmohamed, Munir, Roberts, Amanda, Ryan, David, Schmidt, Amand F, Shah, Anoop D, Shah, Tina, Sofat, Reecha, Takhar, Rohan, Torralbo, Ana, Ullah, Ayath, Walker, Lauren E, Warwick, Alasdair, Wheeler, Eleanor, Wright, Victoria L, Wu, Honghan, Zwierzyna, Magdalena, Patalay, Praveetha, Nitsch, Dorothea, Mathur, Rohini, Partridge, Linda, Wong, Ian C K, Hingorani, Melanie, and Hingorani, Aroon D

Published
2023
Full Text
View/download PDF

21. Genome‐wide association study of inhaled corticosteroid response in admixed children with asthma

Author

Hernandez‐Pacheco, Natalia, Farzan, Niloufar, Francis, Ben, Karimi, Leila, Repnik, Katja, Vijverberg, Susanne J, Soares, Patricia, Schieck, Maximilian, Gorenjak, Mario, Forno, Erick, Eng, Celeste, Oh, Sam S, Pérez‐Méndez, Lina, Berce, Vojko, Tavendale, Roger, Samedy, Lesly‐Anne, Hunstman, Scott, Hu, Donglei, Meade, Kelley, Farber, Harold J, Avila, Pedro C, Serebrisky, Denise, Thyne, Shannon M, Brigino‐Buenaventura, Emerita, Rodriguez‐Cintron, William, Sen, Saunak, Kumar, Rajesh, Lenoir, Michael, Rodriguez‐Santana, Jose R, Celedón, Juan C, Mukhopadhyay, Somnath, Potočnik, Uroš, Pirmohamed, Munir, Verhamme, Katia M, Kabesch, Michael, Palmer, Colin NA, Hawcutt, Daniel B, Flores, Carlos, der Zee, Anke H Maitland‐van, Burchard, Esteban G, and Pino‐Yanes, Maria

Subjects
Biomedical and Clinical Sciences, Immunology, Human Genome, Asthma, Genetics, Clinical Research, Lung, Respiratory, Administration, Inhalation, Adolescent, Adrenal Cortex Hormones, Child, Cytidine Deaminase, DNA-Binding Proteins, Female, GTPase-Activating Proteins, Genome-Wide Association Study, Humans, Male, Minor Histocompatibility Antigens, African American, childhood asthma, exacerbations, Latino, pharmacogenomics, Nutrition and Dietetics, Public Health and Health Services, Allergy
Abstract

BackgroundInhaled corticosteroids (ICS) are the most widely prescribed and effective medication to control asthma symptoms and exacerbations. However, many children still have asthma exacerbations despite treatment, particularly in admixed populations, such as Puerto Ricans and African Americans. A few genome-wide association studies (GWAS) have been performed in European and Asian populations, and they have demonstrated the importance of the genetic component in ICS response.ObjectiveWe aimed to identify genetic variants associated with asthma exacerbations in admixed children treated with ICS and to validate previous GWAS findings.MethodsA meta-analysis of two GWAS of asthma exacerbations was performed in 1347 admixed children treated with ICS (Hispanics/Latinos and African Americans), analysing 8.7 million genetic variants. Those with P ≤ 5 × 10-6 were followed up for replication in 1697 asthmatic patients from six European studies. Associations of ICS response described in published GWAS were followed up for replication in the admixed populations.ResultsA total of 15 independent variants were suggestively associated with asthma exacerbations in admixed populations (P ≤ 5 × 10-6 ). One of them, located in the intergenic region of APOBEC3B and APOBEC3C, showed evidence of replication in Europeans (rs5995653, P = 7.52 × 10-3 ) and was also associated with change in lung function after treatment with ICS (P = 4.91 × 10-3 ). Additionally, the reported association of the L3MBTL4-ARHGAP28 genomic region was confirmed in admixed populations, although a different variant was identified.Conclusions and clinical relevanceThis study revealed the novel association of APOBEC3B and APOBEC3C with asthma exacerbations in children treated with ICS and replicated previously identified genomic regions. This contributes to the current knowledge about the multiple genetic markers determining responsiveness to ICS which could lead in the future the clinical identification of those asthma patients who are not able to respond to such treatment.

Published
2019

22. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records

Author

Abbasizanjani, Hoda, Ahmed, Nida, Ahmed, Badar, Akbari, Ashley, Akinoso-Imran, Abdul Qadr, Allara, Elias, Allery, Freya, Angelantonio, Emanuele Di, Ashworth, Mark, Ayyar-Gupta, Vandana, Babu-Narayan, Sonya, Bacon, Seb, Ball, Steve, Banerjee, Ami, Barber, Mark, Barrett, Jessica, Bennie, Marion, Berry, Colin, Beveridge, Jennifer, Birney, Ewan, Bojanić, Lana, Bolton, Thomas, Bone, Anna, Boyle, Jon, Braithwaite, Tasanee, Bray, Ben, Briffa, Norman, Brind, David, Brown, Katherine, Buch, Maya, Canoy, Dexter, Caputo, Massimo, Carragher, Raymond, Carson, Alan, Cezard, Genevieve, Chang, Jen-Yu Amy, Cheema, Kate, Chin, Richard, Chudasama, Yogini, Cooper, Jennifer, Copland, Emma, Crallan, Rebecca, Cripps, Rachel, Cromwell, David, Curcin, Vasa, Curry, Gwenetta, Dale, Caroline, Danesh, John, Das-Munshi, Jayati, Dashtban, Ashkan, Davies, Alun, Davies, Joanna, Davies, Gareth, Davies, Neil, Day, Joshua, Delmestri, Antonella, Denaxas, Spiros, Denholm, Rachel, Dennis, John, Denniston, Alastair, Deo, Salil, Dhillon, Baljean, Docherty, Annemarie, Dong, Tim, Douiri, Abdel, Downs, Johnny, Dregan, Alexandru, Ellins, Elizabeth A, Elwenspoek, Martha, Falck, Fabian, Falter, Florian, Fan, Yat Yi, Firth, Joseph, Fraser, Lorna, Friebel, Rocco, Gavrieli, Amir, Gerstung, Moritz, Gilbert, Ruth, Gillies, Clare, Glickman, Myer, Goldacre, Ben, Goldacre, Raph, Greaves, Felix, Green, Mark, Grieco, Luca, Griffiths, Rowena, Gurdasani, Deepti, Halcox, Julian, Hall, Nick, Hama, Tuankasfee, Handy, Alex, Hansell, Anna, Hardelid, Pia, Hardy, Flavien, Harris, Daniel, Harrison, Camille, Harron, Katie, Hassaine, Abdelaali, Hassan, Lamiece, Healey, Russell, Hemingway, Harry, Henderson, Angela, Herz, Naomi, Heyl, Johannes, Hidajat, Mira, Higginson, Irene, Hinchliffe, Rosie, Hippisley-Cox, Julia, Ho, Frederick, Hocaoglu, Mevhibe, Hollings, Sam, Horne, Elsie, Hughes, David, Humberstone, Ben, Inouye, Mike, Ip, Samantha, Islam, Nazrul, Jackson, Caroline, Jenkins, David, Jiang, Xiyun, Johnson, Shane, Kadam, Umesh, Kallis, Costas, Karim, Zainab, Kasan, Jake, Katsoulis, Michalis, Kavanagh, Kim, Kee, Frank, Keene, Spencer, Kent, Seamus, Khalid, Sara, Khawaja, Anthony, Khunti, Kamlesh, Killick, Richard, Kinnear, Deborah, Knight, Rochelle, Kolamunnage-Dona, Ruwanthi, Kontopantelis, Evan, Kurdi, Amanj, Lacey, Ben, Lai, Alvina, Lambarth, Andrew, Larzjan, Milad Nazarzadeh, Lawler, Deborah, Lawrence, Thomas, Lawson, Claire, Li, Qiuju, Li, Ken, Llinares, Miguel Bernabeu, Lorgelly, Paula, Lowe, Deborah, Lyons, Jane, Lyons, Ronan, Machado, Pedro, Macleod, Mary Joan, Macleod, John, Malgapo, Evaleen, Mamas, Mamas, Mamouei, Mohammad, Manohar, Sinduja, Mapeta, Rutendo, Martelli, Javiera Leniz, Martos, David Moreno, Mateen, Bilal, McCarthy, Aoife, Melville, Craig, Milton, Rebecca, Mizani, Mehrdad, Moncusi, Marta Pineda, Morales, Daniel, Mordi, Ify, Morrice, Lynn, Morris, Carole, Morris, Eva, Mu, Yi, Mueller, Tanja, Murdock, Lars, Nafilyan, Vahé, Nicholson, George, Nikiphorou, Elena, Nolan, John, Norris, Tom, Norris, Ruth, North, Laura, North, Teri-Louise, O'Connell, Dan, Oliver, Dominic, Oluyase, Adejoke, Olvera-Barrios, Abraham, Omigie, Efosa, Onida, Sarah, Padmanabhan, Sandosh, Palmer, Tom, Pasea, Laura, Patel, Riyaz, Payne, Rupert, Pell, Jill, Petitjean, Carmen, Pherwani, Arun, Pickrell, Owen, Pierotti, Livia, Pirmohamed, Munir, Priedon, Rouven, Prieto-Alhambra, Dani, Proudfoot, Alastair, Quinn, Terry, Quint, Jennifer, Raffetti, Elena, Rahimi, Kazem, Rao, Shishir, Razieh, Cameron, Roberts, Brian, Rogers, Caroline, Rossdale, Jennifer, Salim, Safa, Samani, Nilesh, Sattar, Naveed, Schnier, Christian, Schwartz, Roy, Selby, David, Seminog, Olena, Shabnam, Sharmin, Shah, Ajay, Shelton, Jon, Sheppard, James, Sinha, Shubhra, Skrypak, Mirek, Slapkova, Martina, Sleeman, Katherine, Smith, Craig, Sofat, Reecha, Sosenko, Filip, Sperrin, Matthew, Steeg, Sarah, Sterne, Jonathan, Stoica, Serban, Sudell, Maria, Sudlow, Cathie, Sun, Luanluan, Suseeladevi, Arun Karthikeyan, Sweeting, Michael, Sydes, Matt, Takhar, Rohan, Tang, Howard, Thygesen, Johan, Tilston, George, Tochel, Claire, Toit, Clea du, Tomlinson, Christopher, Toms, Renin, Torabi, Fatemeh, Torralbo, Ana, Townson, Julia, Tufail, Adnan, Tungamirai, Tapiwa, Varma, Susheel, Vollmer, Sebastian, Walker, Venexia, Wang, Tianxiao, Wang, Huan, Warwick, Alasdair, Watkinson, Ruth, Watson, Harry, Whiteley, William, Whittaker, Hannah, Wilde, Harry, Wilkinson, Tim, Williams, Gareth, Williams, Michelle, Williams, Richard, Withnell, Eloise, Wolfe, Charles, Wood, Angela, Wright, Lucy, Wu, Honghan, Wu, Jinge, Wu, Jianhua, Yates, Tom, Zaccardi, Francesco, Zhang, Haoting, Zhang, Huayu, Zuccolo, Luisa, Thygesen, Johan H, Mizani, Mehrdad A, Banerjee, Amitava, Lai, Alvina G, Li, Kezhi, Mateen, Bilal A, Sterne, Jonathan A C, Pagel, Christina, and Whiteley, William N

Published
2022
Full Text
View/download PDF

23. A population study of clinically actionable genetic variation affecting drug response from the Middle East

Author

Jithesh, Puthen Veettil, Abuhaliqa, Mohammed, Syed, Najeeb, Ahmed, Ikhlak, El Anbari, Mohammed, Bastaki, Kholoud, Sherif, Shimaa, Umlai, Umm-Kulthum, Jan, Zainab, Gandhi, Geethanjali, Manickam, Chidambaram, Selvaraj, Senthil, George, Chinnu, Bangarusamy, Dhinoth, Abdel-latif, Rania, Al-Shafai, Mashael, Tatari-Calderone, Zohreh, Estivill, Xavier, and Pirmohamed, Munir

Published
2022
Full Text
View/download PDF

25. Sequential Association Rule Mining Revisited: A Study Directed at Relational Pattern Mining for Multi-morbidity

Author

Vincent-Paulraj, Alexandar, Burnside, Girvan, Coenen, Frans, Pirmohamed, Munir, Walker, Lauren, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Bramer, Max, editor, and Ellis, Richard, editor

Published
2021
Full Text
View/download PDF

26. The status of drug evaluation in older adults in the United Kingdom: Bridging the representation gap.

Author

Walker, Lauren E. and Pirmohamed, Munir

Subjects
*CLINICAL drug trials, *PATIENT selection, *ELDER care, *DIVERSITY & inclusion policies, *CLINICAL trials, *HUMAN research subjects, *POLYPHARMACY, *BIOETHICS, *AGING, *DRUG development, *COMORBIDITY, *LONGEVITY, *GOVERNMENT regulation, *PATIENT participation, *OLD age
Abstract

Older adults are persistently underrepresented in clinical drug trials worldwide, despite increasing multiple long‐term conditions and significant prescribing in this demographic. We discuss systemic challenges such as the exclusion of people with comorbid conditions and the lack of assessment for comorbidities as modifiers of treatment effects and highlight the rising trend of polypharmacy, especially among the oldest age groups, which is linked to a significant percentage of unplanned hospitalizations and medication errors. The consequences of these trends prompted the United Kingdom National Overprescribing review, culminating in a set of recommendations for drug development tailored to older adults. Building on this, two critical reports released in April 2023 by the International Longevity Centre (ILC) and the Nuffield Council on Bioethics (NCOB) are discussed. These reports emphasize the importance of diversity and inclusion in clinical trials, advocating for ethical frameworks and methodologies that cater to the complex needs of older adults. The development of inclusive criteria, innovative statistical methodologies, and the integration of patient‐reported outcomes are needed to address the persistent barriers to older adult participation in research, suggesting that pragmatic trials, exemplified by the UK's RECOVERY trial during the COVID‐19 pandemic, could pave the way for more inclusive research practices. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Urine metabolomics signature reveals novel determinants of adrenal suppression in children taking inhaled corticosteroids to control asthma symptoms.

Author

Tran, Dung T., Chen, Yulu, Zheng, Yi, Hecker, Julian, Hawcutt, Daniel B., Pirmohamed, Munir, Lasky‐Su, Jessica, Wu, Ann C., Tantisira, Kelan G., McGeachie, Michael J., Weiss, Scott T., and Dahlin, Amber

Subjects
ASTHMATICS, FATTY acid oxidation, ASTHMA in children, METABOLOMICS, METABOLITES
Abstract

Background: Asthma is routinely treated with inhaled corticosteroids (ICS). Asthma patients on ICS are at increased risk of adrenal suppression, a potentially serious effect of long‐term glucocorticoid exposure; however, this relationship is poorly understood. Therefore, this study aims to identify metabolite biomarkers related to adrenal suppression in asthma patients taking ICS. Methods: A total of 571 urine metabolites from 200 children with asthma on ICS in the Pharmacogenetics of Adrenal Suppression with Inhaled Steroids (PASS) cohort were profiled. Samples were grouped by peak plasma cortisol measurement as adrenal sufficient (>350 nmol/L) or insufficient (≤350 nmol/L) (outcome). Regression and discriminant‐based statistical models combined with network analyses were utilized to assess relationships between metabolites and the outcome. Finally, prioritized metabolites were validated using data from an ancillary study of the Childhood Asthma Management (CAMP) cohort with similar characteristics to PASS. Results: Ninety metabolites were significantly associated with adrenal suppression, of which 57 also could discriminate adrenal status. While 26 metabolites (primarily steroids) were present at lower levels in the adrenal insufficient patients, 14 were significantly elevated in this group; the top metabolite, mannitol/sorbitol, was previously associated with asthma exacerbations. Network analyses identified unique clusters of metabolites related to steroids, fatty acid oxidation, and nucleoside metabolism, respectively. Four metabolites including urocanic acid, acetylcarnitine, uracil, and sorbitol were validated in CAMP cohort for adrenal suppression. Conclusions: Urinary metabolites differ among asthma patients on ICS, by adrenal status. While steroid metabolites were reduced in patients with poor adrenal function, our findings also implicate previously unreported metabolites involved in amino acid, lipid, and nucleoside metabolism. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

Author

Whitfield, John, Masson, Steven, Liangpunsakul, Suthat, Hyman, Jessica, Mueller, Sebastian, Aithal, Guruprasad, Eyer, Florian, Gleeson, Dermot, Thompson, Andrew, Stickel, Felix, Soyka, Michael, Daly, Ann, Cordell, Heather, Liang, Tiebing, Foroud, Tatiana, Lumeng, Lawrence, Pirmohamed, Munir, Nalpas, Bertrand, Bence, Camille, Jacquet, Jean-Marc, Louvet, Alexandre, Moirand, Romain, Nahon, Pierre, Naveau, Sylvie, Perney, Pascal, Podevin, Philippe, Haber, Paul, Seitz, Helmut, Day, Christopher, Mathurin, Philippe, Morgan, Timothy, and Seth, Devanshi

Subjects
Abstinence, Alcohol, Aspartate aminotransferase, Cirrhosis, Gamma glutamyl transferase, Adult, Alcohol Abstinence, Alcohol Drinking, Area Under Curve, Aspartate Aminotransferases, Bilirubin, Biomarkers, Case-Control Studies, Clinical Enzyme Tests, Europe, Female, Humans, International Normalized Ratio, Liver Cirrhosis, Alcoholic, Liver Function Tests, Male, Middle Aged, Predictive Value of Tests, ROC Curve, Reproducibility of Results, Risk Factors, Sex Factors, United States, gamma-Glutamyltransferase
Abstract

Laboratory tests can play an important role in assessment of alcoholic patients, including for evaluation of liver damage and as markers of alcohol intake. Evidence on test performance should lead to better selection of appropriate tests and improved interpretation of results. We compared laboratory test results from 1578 patients between cases (with alcoholic cirrhosis; 753 men, 243 women) and controls (with equivalent lifetime alcohol intake but no liver disease; 439 men, 143 women). Comparisons were also made between 631 cases who had reportedly been abstinent from alcohol for over 60 days and 364 who had not. ROC curve analysis was used to estimate and compare tests ability to distinguish patients with and without cirrhosis, and abstinent and drinking cases. The best tests for presence of cirrhosis were INR and bilirubin, with areas under the ROC curve (AUCs) of 0.91 ± 0.01 and 0.88 ± 0.01, respectively. Confining analysis to patients with no current or previous ascites gave AUCs of 0.88 ± 0.01 for INR and 0.85 ± 0.01 for bilirubin. GGT and AST showed discrimination between abstinence and recent drinking in patients with cirrhosis, including those without ascites, when appropriate (and for GGT, sex-specific) limits were used. For AST, a cut-off limit of 85 units/L gave 90% specificity and 37% sensitivity. For GGT, cut-off limits of 288 units/L in men and 138 units/L in women gave 90% specificity for both and 40% sensitivity in men, 63% sensitivity in women. INR and bilirubin show the best separation between patients with alcoholic cirrhosis (with or without ascites) and control patients with similar lifetime alcohol exposure. Although AST and GGT are substantially increased by liver disease, they can give useful information on recent alcohol intake in patients with alcoholic cirrhosis when appropriate cut-off limits are used.

Published
2018

32. Glycolysis: An early marker for vancomycin‐specific T‐cell activation

Author

Gardner, Joshua, primary, Hammond, Sean, additional, Jensen, Rebecca, additional, Gibson, Andrew, additional, Krantz, Matthew S., additional, Ardern‐Jones, Michael, additional, Phillips, Elizabeth J., additional, Pirmohamed, Munir, additional, Chadwick, Amy E., additional, Betts, Catherine, additional, and Naisbitt, Dean J., additional

Published
2024
Full Text
View/download PDF

34. HLA Class-II‒Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients

Author

Zhao, Qing, Almutairi, Mubarak, Tailor, Arun, Lister, Adam, Harper, Nicolas, Line, James, Meng, Xiaoli, Pratoomwun, Jirawat, Jaruthamsophon, Kanoot, Sukasem, Chonlaphat, Sun, Yonghu, Sun, Lele, Ogese, Monday O., MacEwan, David J., Pirmohamed, Munir, Liu, Jianjun, Ostrov, David A., Liu, Hong, Zhang, Furen, and Naisbitt, Dean J.

Published
2021
Full Text
View/download PDF

35. Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children

Author

Felgner, Jiin, Jain, Aarti, Nakajima, Rie, Liang, Li, Jasinskas, Algis, Gotuzzo, Eduardo, Vinetz, Joseph M, Miyajima, Fabio, Pirmohamed, Munir, Hassan-Hanga, Fatimah, Umoru, Dominic, Jibir, Binta Wudil, Gambo, Safiya, Olateju, Kudirat, Felgner, Philip L, Obaro, Stephen, and Davies, D Huw

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Microbiology, Clinical Sciences, Medical Microbiology, Clinical Research, Rare Diseases, Infectious Diseases, Digestive Diseases, Vaccine Related, Prevention, Pediatric, Emerging Infectious Diseases, Biodefense, Infection, Good Health and Well Being, Antibodies, Bacterial, Child, Child, Preschool, Enzyme-Linked Immunosorbent Assay, Hemolysin Proteins, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Infant, Lipopolysaccharides, Nigeria, ROC Curve, Salmonella typhi, Sensitivity and Specificity, Serologic Tests, Typhoid Fever, Medical and Health Sciences, Tropical Medicine, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Improved serodiagnostic tests for typhoid fever (TF) are needed for surveillance, to facilitate patient management, curb antibiotic resistance, and inform public health programs. To address this need, IgA, IgM and IgG ELISAs using Salmonella enterica serovar Typhi (S. Typhi) lipopolysaccharide (LPS) and hemolysin E (t1477) protein were conducted on 86 Nigerian pediatric TF and 29 non-typhoidal Salmonella (NTS) cases, 178 culture-negative febrile cases, 28 "other" (i.e., non-Salmonella) pediatric infections, and 48 healthy Nigerian children. The best discrimination was achieved between TF and healthy children. LPS-specific IgA and IgM provided receiver operator characteristic areas under the curve (ROC AUC) values of 0.963 and 0.968, respectively, and 0.978 for IgA+M combined. Similar performance was achieved with t1477-specific IgA and IgM (0.968 and 0.968, respectively; 0.976 combined). IgG against LPS and t1477 was less accurate for discriminating these groups, possibly as a consequence of previous exposure, although ROC AUC values were still high (0.928 and 0.932, respectively). Importantly, discrimination between TF and children with other infections was maintained by LPS-specific IgA and IgM (AUC = 0.903 and 0.934, respectively; 0.938 combined), and slightly reduced for IgG (0.909), while t1477-specific IgG performed best (0.914). A similar pattern was seen when comparing TF with other infections from outside Nigeria. The t1477 may be recognized by cross-reactive antibodies from other acute infections, although a robust IgG response may provide some diagnostic utility in populations where incidence of other infections is low, such as in children. The data are consistent with IgA and IgM against S. Typhi LPS being specific markers of acute TF.

Published
2017

39. Genetic Determinants of Thiazide‐Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances – A Genome‐Wide Evaluation of the UK Biobank.

Author

Asiimwe, Innocent G., Walker, Lauren, Sofat, Reecha, Jorgensen, Andrea L., and Pirmohamed, Munir

Subjects
LOCUS (Genetics), GENOTYPE-environment interaction, GENETIC variation, HYPERURICEMIA, HYPERGLYCEMIA, BLOOD sugar
Abstract

Thiazide diuretics, widely used in hypertension, cause a variety of adverse reactions, including hyperglycemia, hyperuricemia, and electrolyte abnormalities. In this study, we aimed to identify genetic variants that interact with thiazide‐use to increase the risk of these adverse reactions. Using UK Biobank data, we first performed genomewide variance quantitative trait locus (vQTL) analysis of ~ 6.2 million SNPs on 95,493 unrelated hypertensive White British participants (24,313 on self‐reported bendroflumethiazide treatment at recruitment) for 2 blood (glucose and urate) and 2 urine (potassium and sodium) biomarkers. Second, we conducted direct gene–environment interaction (GEI) tests on the significant (P < 2.5 × 10−9) vQTLs, included a second UK Biobank cohort comprising 13,647 unrelated hypertensive White British participants (3,478 on thiazides other than bendroflumethiazide) and set significance at P = 0.05 divided by the number of vQTL SNPs tested for GEIs. The vQTL analysis identified eight statistically significant SNPs for blood glucose (5 SNPs) and serum urate (3 SNPs), with none being identified for the urinary biomarkers. Two of the SNPs (1 glucose SNP: CDKAL1 intron rs35612982, GEI P = 6.24 × 10−3; and 1 serum urate SNP: SLC2A9 intron rs938564, GEI P = 4.51 × 10−4) demonstrated significant GEI effects in the first, but not the second, cohort. Both genes are biologically plausible candidates, with the SLC2A9‐mediated interaction having been previously reported. In conclusion, we used a two‐stage approach to detect two biologically plausible genetic loci that can interact with thiazides to increase the risk of thiazide‐associated biochemical abnormalities. Understanding how environmental exposures (including medications such as thiazides) and genetics interact, is an important step toward precision medicine and improved patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.

Author

Ingelman‐Sundberg, Magnus and Pirmohamed, Munir

Subjects
*INDIVIDUALIZED medicine, *DRUG analysis, *THERAPEUTICS, *WHOLE genome sequencing, *DRUG therapy, *DRUG metabolism
Abstract

Pharmacogenomics is the examination of how genetic variation influences drug metabolism and response, in terms of both efficacy and safety. In cardiovascular disease, patient‐specific diplotypes determine phenotypes, thereby influencing the efficacy and safety of drug treatments, including statins, antiarrhythmics, anticoagulants and antiplatelets. Notably, polymorphisms in key genes, such as CYP2C9, CYP2C19, VKORC1 and SLCO1B1, significantly impact the outcomes of treatment with clopidogrel, warfarin and simvastatin. Furthermore, the CYP2C19 polymorphism influences the pharmacokinetics and safety of the novel hypertrophic cardiomyopathy inhibitor, mavacamten. In this review, we critically assess the clinical application of pharmacogenomics in cardiovascular disease and delineate present and future utilization of pharmacogenomics. This includes insights into identifying missing heritability, the integration of whole genome sequencing and the application of polygenic risk scores to enhance the precision of personalized drug therapy. Our discussion encompasses health economic analyses that underscore the cost benefits associated with pre‐emptive genotyping for warfarin and clopidogrel treatments, albeit acknowledging the need for further research in this area. In summary, we contend that cardiovascular pharmacogenomic analyses are underpinned by a wealth of evidence, and implementation is already occurring for some of these gene–drug pairs, but as with any area of medicine, we need to continually gather more information to optimize the use of pharmacogenomics in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. SJS/TEN 2019: From science to translation

Author

Chang, Wan-Chun, Abe, Riichiro, Anderson, Paul, Anderson, Wanpen, Ardern-Jones, Michael R., Beachkofsky, Thomas M., Bellón, Teresa, Biala, Agnieszka K., Bouchard, Charles, Cavalleri, Gianpiero L., Chapman, Nicole, Chodosh, James, Choi, Hyon K., Cibotti, Ricardo R., Divito, Sherrie J., Dewar, Karen, Dehaeck, Ulrike, Etminan, Mahyar, Forbes, Diane, Fuchs, Esther, Goldman, Jennifer L., Holmes, James H., IV, Hope, Elyse A., Hung, Shuen-Iu, Hsieh, Chia-Ling, Iovieno, Alfonso, Jagdeo, Julienne, Kim, Mee Kum, Koelle, David M., Lacouture, Mario E., Le Pallec, Sophie, Lehloenya, Rannakoe J., Lim, Robyn, Lowe, Angie, McCawley, Jean, McCawley, Julie, Micheletti, Robert G., Mockenhaupt, Maja, Niemeyer, Katie, Norcross, Michael A., Oboh, Douglas, Olteanu, Cristina, Pasieka, Helena B., Peter, Jonathan, Pirmohamed, Munir, Rieder, Michael, Saeed, Hajirah N., Shear, Neil H., Shieh, Christine, Straus, Sabine, Sukasem, Chonlaphat, Sung, Cynthia, Trubiano, Jason A., Tsou, Sheng-Ying, Ueta, Mayumi, Volpi, Simona, Wan, Chen, Wang, Hongsheng, Wang, Zhao-Qing, Weintraub, Jessica, Whale, Cindy, Wheatley, Lisa M., Whyte-Croasdaile, Sonia, Williams, Kristina B., Wright, Galen, Yeung, Sonia N., Zhou, Li, Chung, Wen-Hung, Phillips, Elizabeth J., and Carleton, Bruce C.

Published
2020
Full Text
View/download PDF

45. Updates in SJS/TEN: collaboration, innovation, and community

Author

Marks, Madeline E., primary, Botta, Ramya Krishna, additional, Abe, Riichiro, additional, Beachkofsky, Thomas M., additional, Boothman, Isabelle, additional, Carleton, Bruce C., additional, Chung, Wen-Hung, additional, Cibotti, Ricardo R., additional, Dodiuk-Gad, Roni P., additional, Grimstein, Christian, additional, Hasegawa, Akito, additional, Hoofnagle, Jay H., additional, Hung, Shuen-Iu, additional, Kaffenberger, Benjamin, additional, Kroshinsky, Daniela, additional, Lehloenya, Rannakoe J., additional, Martin-Pozo, Michelle, additional, Micheletti, Robert G., additional, Mockenhaupt, Maja, additional, Nagao, Keisuke, additional, Pakala, Suman, additional, Palubinsky, Amy, additional, Pasieka, Helena B., additional, Peter, Jonathan, additional, Pirmohamed, Munir, additional, Reyes, Melissa, additional, Saeed, Hajirah N., additional, Shupp, Jeffery, additional, Sukasem, Chonlaphat, additional, Syu, Jhih Yu, additional, Ueta, Mayumi, additional, Zhou, Li, additional, Chang, Wan-Chun, additional, Becker, Patrice, additional, Bellon, Teresa, additional, Bonnet, Kemberlee, additional, Cavalleri, Gianpiero, additional, Chodosh, James, additional, Dewan, Anna K., additional, Dominguez, Arturo, additional, Dong, Xinzhong, additional, Ezhkova, Elena, additional, Fuchs, Esther, additional, Goldman, Jennifer, additional, Himed, Sonia, additional, Mallal, Simon, additional, Markova, Alina, additional, McCawley, Kerry, additional, Norton, Allison E., additional, Ostrov, David, additional, Phan, Michael, additional, Sanford, Arthur, additional, Schlundt, David, additional, Schneider, Daniel, additional, Shear, Neil, additional, Shinkai, Kanade, additional, Tkaczyk, Eric, additional, Trubiano, Jason A., additional, Volpi, Simona, additional, Bouchard, Charles S., additional, Divito, Sherrie J., additional, and Phillips, Elizabeth J., additional

Published
2023
Full Text
View/download PDF

46. A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment

Author

Ogese, Monday O, primary, Lister, Adam, additional, Farrell, Liam, additional, Gardner, Joshua, additional, Kafu, Laila, additional, Ali, Serat-E, additional, Gibson, Andrew, additional, Hillegas, Aimee, additional, Meng, Xiaoli, additional, Pirmohamed, Munir, additional, Williams, Geoffrey S, additional, Sakatis, Melanie Z, additional, and Naisbitt, Dean J, additional

Published
2023
Full Text
View/download PDF

47. Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

Author

King, Charlotte, McKenna, Amanda, Farzan, Niloufar, Vijverberg, Susanne J., van der Schee, Marc P., Maitland-van der Zee, Anke H., Arianto, Lambang, Bisgaard, Hans, BØnnelykke, Klaus, Berce, Vojko, PotoČnik, Uros, Repnik, Katja, Carleton, Bruce, Daley, Denise, Chew, Fook Tim, Chiang, Wen Chin, Sio, Yang Yie, Cloutier, Michelle M., Den Dekker, Herman T., Duijts, Liesbeth, de Jongste, Johan C., Dijk, F. Nicole, Flores, Carlos, Hernandez-Pacheco, Natalia, Mukhopadhyay, Somnath, Basu, Kaninika, Tantisira, Kelan G., Verhamme, Katia M., Celedón, Juan C., Forno, Erick, Canino, Glorisa, Francis, Ben, Pirmohamed, Munir, Sinha, Ian, and Hawcutt, Daniel B.

Published
2020
Full Text
View/download PDF

49. Session 10: Clinical pathology; dermatology; primary practice and the profession

Author

Miles, James, primary, Nielsen, Michelle Brønniche Møller, additional, Nielsen, Lise Nikolic, additional, Aðalsteinsdóttir, Kristín, additional, Ólafsdóttir, Arna, additional, Santiago, Raquel, additional, Feo, Luis, additional, Pastor, Josep, additional, Sanchez, Monica, additional, Bercianos, Alba, additional, Puig, Jordi, additional, Donovan, Zoe, additional, Greaves, Michelle, additional, Wright, Andrea, additional, Gildea, Edwina, additional, Longstaff, Louise, additional, Wyn, Robin, additional, Nagda, Nirav, additional, DiPietrantonio, Kristina, additional, Enstone, Ashley, additional, Riley, Danielle, additional, Cadiergues, Marie-Christine, additional, Alexander, Akash, additional, Radke, Heidi, additional, Davies, Heather, additional, Pinchbeck, Gina, additional, Noble, P-J.M, additional, Pirmohamed, Munir, additional, Killick, David, additional, Houlton, John, additional, Malkani, Rachel, additional, Tipton, Emma, additional, James, Lynne, additional, Betton, Vicki, additional, Wensley, Sean, additional, Moffat, Archie, additional, Graham, Peter, additional, Rogers-Smith, Emma, additional, Bjöersdorff, Anneli, additional, and Battersby, Ian, additional

Published
2021
Full Text
View/download PDF

50. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Author

Cheung, Vincent Ting Fung, Gupta, Tarun, Olsson-Brown, Anna, Subramanian, Sreedhar, Sasson, Sarah Christina, Heseltine, Jonathan, Fryer, Eve, Collantes, Elena, Sacco, Joseph J., Pirmohamed, Munir, Simmons, Alison, Klenerman, Paul, Tuthill, Mark, Protheroe, Andrew S., Chitnis, Meenali, Fairfax, Benjamin Peter, Payne, Miranda Jane, Middleton, Mark Ross, and Brain, Oliver

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results